BMO Capital Maintains Outperform on Intellia Therapeutics, Raises Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Kostas Biliouris maintains an Outperform rating on Intellia Therapeutics (NTLA) and raises the price target from $62 to $70.
May 10, 2024 | 3:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital analyst Kostas Biliouris reaffirmed an Outperform rating on Intellia Therapeutics and increased the price target from $62 to $70, indicating a positive outlook on the company's stock.
The increase in price target by a reputable analyst suggests a strong belief in the company's future performance. This typically leads to increased investor confidence and can drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100